Thus, the hot spot residues of NHR2 represented a target for developing inhibitors of RUNX1/ETO tetramerization and a molecular intervention in t(8;21)-dependent AML that had not yet been addressed. The gene discussed is RUNX1; the disease is acute myeloid leukemia.